HDAC2抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using HDAC2 mouse mAb against Hela (1), Jurat (2), HepG2 (3), Hek293 (4), K562 (5), MCF-7 (6), NIH3T3 (7), COS7 (8) and PC-12 (9) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of Hela cells using HDAC2 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human cervical cancer tissues using HDAC2 mouse mAb with DAB staining.    

  
  

Histone deacetylase 2 (HDAC2) is a member of the class I histone deacetylase family, which plays a critical role in epigenetic regulation by removing acetyl groups from histone proteins. This enzymatic activity promotes chromatin condensation, leading to transcriptional repression of target genes. HDAC2 is involved in diverse cellular processes, including cell cycle progression, differentiation, and apoptosis, and its dysregulation has been linked to cancers, neurodegenerative disorders, and metabolic diseases. Studies highlight its role in cancer progression, where overexpression of HDAC2 correlates with poor prognosis and resistance to therapy. In neurodegenerative contexts, reduced HDAC2 levels are associated with impaired synaptic plasticity and memory formation.

HDAC2 antibodies are essential tools for studying its expression, localization, and function in both normal and pathological states. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry, and chromatin immunoprecipitation (ChIP) to investigate HDAC2 protein levels, tissue distribution, and interactions with DNA or other regulatory proteins. Validated HDAC2 antibodies are critical for ensuring specificity, as cross-reactivity with other HDAC isoforms (e.g., HDAC1) can confound results. Researchers also utilize these antibodies to explore the therapeutic potential of HDAC inhibitors, which are being investigated for cancer and neurological treatments. Monoclonal and polyclonal HDAC2 antibodies are available, each offering distinct advantages depending on the experimental design.